Skip to main content
Premium Trial:

Request an Annual Quote

Genome Canada Startup Emerillon Therapeutics to Acquire HemaX Genome in All-Stock Transaction

NEW YORK, Oct. 10 (GenomeWeb News) - Emerillon Therapeutics will acquire HemaX Genome in an all-stock transaction, the Canadian companies said last week.


Under the agreement, Emerillon will acquire all outstanding shares of exchange for Emerillon shares. In addition, GeneChem Technologies, one of HemaX's venture capital investors, will make an equity investment in Emerillon.


Emerillon, which studies genes associated with human complex diseases, was founded in 2003 as a spinoff from Xenon Pharmaceuticals with funding from Genome Canadaand Genome Quebec. "This is the first major involvement of venture capital investment in a Genome Quebec initiated company," said Paul L'Archeveque, president of Genome Quebec, in a statement.


HemaX has been focusing on genes of medical interest on the X chromosome and other genes responsible for diseases with unequal gender distribution.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.